Literature DB >> 15827168

Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.

Xuemin Chen1, Michael T Rock, Jason Hammonds, James Tartaglia, Ayumi Shintani, Jeff Currier, Bonnie Slike, James E Crowe, Mary Marovich, Paul Spearman.   

Abstract

Live-vector-based human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation. Live vectors that carry an intact gag gene are capable of eliciting HIV pseudovirion particle formation from infected host cells. The impact of pseudovirion particle formation on the immune response generated by live HIV vaccine vectors has not been established. In this study, a canarypox HIV vaccine candidate vector expressing HIV gag and env genes, vCP205, was modified by the introduction of a glycine-to-alanine coding change in the N-terminal myristylation site of gag to create Myr- vCP205. This substitution effectively eliminated particle formation without altering the level of protein production. vCP205 and Myr- vCP205 were then directly compared for the ability to induce HIV-specific immune responses in mice. The particle-competent vector vCP205 elicited higher levels of CD8+ T-cell responses, as indicated by gamma interferon enzyme-linked immunospot (ELISPOT) assay and intracellular cytokine staining. Humoral responses to Gag and Env were also markedly higher from animals immunized with the particle-competent vector. Furthermore, HIV-specific CD4+ T-cell responses were greater among animals immunized with the particle-competent vector. Using a human dendritic cell model of antigen presentation in vitro, vCP205 generated greater ELISPOT responses than Myr- vCP205. These results demonstrate that pseudovirion particle production by live-vector HIV vaccines enhances HIV-specific cellular and humoral immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827168      PMCID: PMC1082749          DOI: 10.1128/JVI.79.9.5537-5547.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  CpG motifs of DNA vaccines induce the expression of chemokines and MHC class II molecules on myocytes.

Authors:  A C Stan; S Casares; T D Brumeanu; D M Klinman; C A Bona
Journal:  Eur J Immunol       Date:  2001-01       Impact factor: 5.532

2.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

3.  Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding.

Authors:  J E Garrus; U K von Schwedler; O W Pornillos; S G Morham; K H Zavitz; H E Wang; D A Wettstein; K M Stray; M Côté; R L Rich; D G Myszka; W I Sundquist
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

4.  Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques.

Authors:  Charlotta Nilsson; Gerd Sutter; Lilian Walther-Jallow; Peter Ten Haaft; Lennart Åkerblom; Jonathan Heeney; Volker Erfle; Per Böttiger; Gunnel Biberfeld; Rigmor Thorstensson
Journal:  J Gen Virol       Date:  2002-04       Impact factor: 3.891

5.  Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Authors:  I Ourmanov; C R Brown; B Moss; M Carroll; L Wyatt; L Pletneva; S Goldstein; D Venzon; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.

Authors:  C Lapham; B Golding; J Inman; R Blackburn; J Manischewitz; P Highet; H Golding
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

7.  ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Authors:  R Pal; D Venzon; N L Letvin; S Santra; D C Montefiori; N R Miller; E Tryniszewska; M G Lewis; T C VanCott; V Hirsch; R Woodward; A Gibson; M Grace; E Dobratz; P D Markham; Z Hel; J Nacsa; M Klein; J Tartaglia; G Franchini
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

Authors:  R B Belshe; C Stevens; G J Gorse; S Buchbinder; K Weinhold; H Sheppard; D Stablein; S Self; J McNamara; S Frey; J Flores; J L Excler; M Klein; R E Habib; A M Duliege; C Harro; L Corey; M Keefer; M Mulligan; P Wright; C Celum; F Judson; K Mayer; D McKirnan; M Marmor; G Woody
Journal:  J Infect Dis       Date:  2001-04-10       Impact factor: 5.226

9.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

10.  Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells.

Authors:  Z Y Fang; K Limbach; J Tartaglia; J Hammonds; X Chen; P Spearman
Journal:  Virology       Date:  2001-12-20       Impact factor: 3.616

View more
  8 in total

1.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Aaron Wallace; Kim West; Alan L Rothman; Francis A Ennis; Shan Lu; Shixia Wang
Journal:  Hum Vaccin Immunother       Date:  2013-08-13       Impact factor: 3.452

3.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

4.  Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James E Robinson; Mary Barnes; Cristian Apetrei; James M Binley
Journal:  Virology       Date:  2014-05       Impact factor: 3.616

5.  Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.

Authors:  Xiugen Zhang; Farah Cassis-Ghavami; Mike Eller; Jeff Currier; Bonnie M Slike; Xuemin Chen; James Tartaglia; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

6.  Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.

Authors:  Ema T Crooks; Tommy Tong; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

7.  The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods.

Authors:  Shixia Wang; Chunghua Zhang; Lu Zhang; Jun Li; Zuhu Huang; Shan Lu
Journal:  Vaccine       Date:  2008-03-06       Impact factor: 3.641

8.  A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.

Authors:  Lydia R Meador; Sarah A Kessans; Jacquelyn Kilbourne; Karen V Kibler; Giuseppe Pantaleo; Mariano Esteban Roderiguez; Joseph N Blattman; Bertram L Jacobs; Tsafrir S Mor
Journal:  Virology       Date:  2017-04-28       Impact factor: 3.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.